The UK Medicines and Healthcare products Regulatory Agency has announced its largest single batch of pharmaceutical licensing approvals in 18 months, granting 47 new manufacturing and wholesale dealer licences. This significant regulatory decision, published in December 2024, comprises 28 manufacturing licences and 19 wholesale dealer licences, reflecting robust industry growth and sustained confidence in UK pharmaceutical manufacturing capabilities.
The scale of these approvals indicates accelerating expansion within the UK pharmaceutical sector, as companies invest in new production facilities and distribution infrastructure. Each licensed facility must demonstrate compliance with international Good Manufacturing Practice standards, ensuring product quality and safety. This approval surge suggests industry confidence in post-Brexit market conditions and signals potential improvements in medicine availability and supply chain resilience across the UK healthcare system.
Read the full article on GMJ Newsroom.
Was this article helpful?
